- Home
- SOR vs ORIC Comparison
SOR vs ORIC Comparison
Compare SOR & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOR
- ORIC
- Stock Information
- Founded
- SOR 1968
- ORIC 2014
- Country
- SOR United States
- ORIC United States
- Employees
- SOR N/A
- ORIC N/A
- Industry
- SOR Investment Managers
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- SOR Finance
- ORIC Health Care
- Exchange
- SOR Nasdaq
- ORIC Nasdaq
- Market Cap
- SOR 328.9M
- ORIC 362.9M
- IPO Year
- SOR N/A
- ORIC 2020
- Fundamental
- Price
- SOR $43.08
- ORIC $5.31
- Analyst Decision
- SOR
- ORIC Strong Buy
- Analyst Count
- SOR 0
- ORIC 8
- Target Price
- SOR N/A
- ORIC $18.83
- AVG Volume (30 Days)
- SOR 16.2K
- ORIC 583.2K
- Earning Date
- SOR 01-01-0001
- ORIC 05-05-2025
- Dividend Yield
- SOR 7.24%
- ORIC N/A
- EPS Growth
- SOR N/A
- ORIC N/A
- EPS
- SOR 6.50
- ORIC N/A
- Revenue
- SOR N/A
- ORIC N/A
- Revenue This Year
- SOR N/A
- ORIC N/A
- Revenue Next Year
- SOR N/A
- ORIC N/A
- P/E Ratio
- SOR $6.41
- ORIC N/A
- Revenue Growth
- SOR N/A
- ORIC N/A
- 52 Week Low
- SOR $36.41
- ORIC $3.90
- 52 Week High
- SOR $42.75
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- SOR 66.81
- ORIC 48.02
- Support Level
- SOR $41.47
- ORIC $4.52
- Resistance Level
- SOR $42.58
- ORIC $5.59
- Average True Range (ATR)
- SOR 0.97
- ORIC 0.49
- MACD
- SOR 0.19
- ORIC 0.07
- Stochastic Oscillator
- SOR 91.98
- ORIC 57.25
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.